Table 1.
Characteristics of trials (or parts of trials) eligible for comparison A
| Trial | Years of accrual | Number of men randomised | De novo or relapsed M1? | Treatment | Control | Median follow-up (survival) |
|---|---|---|---|---|---|---|
| Radiotherapy | ADT | |||||
| Radiotherapy + ADT vs ADT | ||||||
| STAMPEDE A1 [11] (arm H vs arm A) | 2013–2016 | 1694 | De novo | 36 Gy, 6 fractions over 6 wk or 55 Gy, 20 fractions over 4 wk | ADT (LHRH agonist or antagonist or orchiectomy) | 41.9 mo |
| HORRAD [12] | 2004–2014 | 432 | De novo | 70 Gy, 35 fractions over 7 wk or 57.76 Gy, 19 fractions over 6 wk | ADT (LHRH agonist or orchiectomy) | 47 mo |
| PEACE-1A1 (NCT01957436) | 2013–2018* | 234 | De novo | 74 Gy, 37 fractions within 7–8 wk | ADT (LHRH agonist or antagonist or orchiectomy) | Not yet available |
ADT = androgen deprivation therapy; LHRH = luteinising hormone-releasing hormone. *PEACE-1 closed to accrual between submission and acceptance of the manuscript